Epitope-specific therapy for Graves' disease with immune-modulating peptides and siglec ligands

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461385
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Endocrinology
• Research Institution: Wakayama Medical University
• Principal Investigator: Inaba Hidefumi 和歌山県立医科大学, 医学部, 講師 (70447770)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: バセドウ病 / TSH受容体 / HLA / T細胞

Outline of Final Research Achievements

The aim of this study is 1) to elucidate epitope presentation in Graves’ disease (GD), and 2) to establish epitope specific therapy for GD. We have reported that human TSH receptor (AA78-94) was an important epitope. Therapeutic role of the mutant human TSH receptor peptide: 37m, was evaluated in this study. GD model of HLA-DR3 transgenic mice was treated with 37m. The thyrotoxicosis was improved, TRAb production was suppressed, and proportion of regulatory T-cells in the spleen was increased. Therefore, immune-regulatory effects of 37m were observed.

Free Research Field

内分泌学